Clinical trials: Drug Users
Healthy, Drug Abuse
Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users
The purpose of this study is to assess the abuse potential of single doses of pitolisant relative to phentermine HCl and placebo, when administered to healthy, non-dependent, recreational stimulant users.
- Trial name
- NCT03152123
- Testing
- Pitolisant, Phentermine
- Where
- Canada
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Bioprojet
Chronic Use of Acid Suppressive Medication, GORD
On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication
The purpose of this study is to investigate several aspects of chronic use of acid suppressing medication: dependence on maintenance therapy, the possibilities for on-demand use, and predictors (patient characteristics) for daily…
- Conditions
- Chronic Use of Acid Suppressive Medication, GORD, GERD, Reflux
- Trial name
- NCT00161096
- Testing
- pantoprazole 20 mg (drug)
- Volunteers
- 276 people
- Sponsor
- UMC Utrecht
Morphinan Opioid Overdose
Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid Overdose
The purpose of this study is to determine which route of administration is better for treatment of opioid overdosed patients
- Trial name
- NCT01293058
- Testing
- Intranasal naloxone, Intravenous
- Where
- Iran
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Methamphetamine Dependence, Methamphetamine Withdrawal
Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
Methamphetamine use has escalated in recent years. Methamphetamine use has also spread throughout the country. Although much information has been gathered on the treatment of cocaine abuse, very little information has been…
- Trial name
- NCT00653263
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Arkansas
Opiate Dependence
Linking Hospitalized Injection Drug Users to Buprenorphine
This study tests whether starting Suboxone (buprenorphine) during a medical hospitalization, and then providing an appointment (a "link") for after discharge to maintenance buprenorphine in an outpatient setting will reduce HIV…
- Trial name
- NCT00987961
- Testing
- Linkage
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Butler Hospital
Opioid Use Disorder, Alcohol Use Disorder
Removing Barriers: Community Partnering for Innovative Solutions to the Opioid Crisis
The opioid epidemic has become one of America's deadliest crises, surpassing car crashes, firearms, and HIV/AIDS as a leading cause of death for Americans under fifty years of age.
- Conditions
- Opioid Use Disorder, Alcohol Use Disorder, Health Risk Behaviors, Criminal Behavior
- Trial name
- RB (NCT05665179)
- Testing
- Removing Barriers to Recovery
- Where
- 2 sites in United States
- Volunteers
- 800 people
- Sponsor
- University of Michigan
Abuse, Drug
A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users
The primary objective of this study was to evaluate the abuse potential of single doses of cebranopadol (GRT6005) relative to hydromorphone (immediate-release formulation [IR] and placebo in 48 non-dependent recreational opioid…
- Trial name
- NCT03757559
- Testing
- Cebranopadol 100 micrograms, Cebranopadol 400 micrograms, Hydromorphone hydrochloride 4 milligrams
- Where
- Canada
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Depression, Anxiety
More Individualized Care: Assessment and Recovery Through Engagement
The MI-CARE trial tests 12 months of telephone-based nurse care management for patients with depressive symptoms who take or have taken opioids at some time.
- Conditions
- Depression, Anxiety, Opioid-Related Disorders, Pain, Chronic
- Trial name
- MI-CARE (NCT05122676)
- Testing
- More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)
- Where
- 2 sites in United States
- Volunteers
- 805 people
- Sponsor
- Kaiser Permanente
Healthy Recreational Drug Users
Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users
This placebo- and active controlled study will investigate the abuse potential of ACT-541468 in healthy recreational drug users
- Trial name
- NCT03657355
- Testing
- ACT-541468, Suvorexant, Zolpidem
- Where
- 2 sites in United States, Canada
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Arterial Hypertension
OPsumit USers Registry
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with…
- Trial name
- OPUS (NCT02126943)
- Testing
- Opsumit (macitentan)
- Where
- 146 sites in United States, Puerto Rico
- Volunteers
- 2,686 people
- Sponsor
- Actelion
Smoking Behaviors, Smoking ( Cigarette)
A Study to Assess Nicotine Uptake From a Menthol Electronic Nicotine Delivery System Product
This will be a randomized, open-label, 2-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics [PD]), and plasma nicotine…
- Conditions
- Smoking Behaviors, Smoking ( Cigarette), Tobacco Use, Abuse Liability
- Trial name
- NCT07881848
- Testing
- Menthol 5%, Combustible cigarette
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Vitamin D Deficiency, Osteopenia
Monitored vs Standard Supplementation of Vitamin D in Preterm Infants
The purpose of this study is to determine wheather the monitored vitamin D (vit D) therapy is safer and more effective than standard therapy in pretrem infants.
- Conditions
- Vitamin D Deficiency, Osteopenia, Nephrolithiasis, Drug Overdose
- Trial name
- MOSVID (NCT03087149)
- Testing
- monitored vit D supplementation, standard vit D supplementation
- Where
- Poland
- Volunteers
- 109 people
- Sponsor
- Princess Anna Mazowiecka Hospital, Warsaw, Poland
HIV, Substance Abuse, Intravenous
Contingency Management in the Delivery of HAART to Drug Users in Chennai, India
Drug use (DU) is a major risk factor for HIV infection in many regions of the world. However, as highly active antiretroviral therapy (HAART) has been rolled out in South and South East Asia, less than 2% of individuals initiated…
- Trial name
- NCT01031745
- Testing
- Contingency, Prize bowl drawings
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Johns Hopkins University
Drug Dependence
CB1R in Synthetic Psychoactive Cannabinoids
The purpose of this research study is to determine whether the CB1R availability is lower in synthetic psychoactive cannabinoid subjects using the most widely available synthetic psychoactive cannabinoids at the time the study is…
- Trial name
- CB1R in Spice (NCT03539575)
- Testing
- [11-C]OMAR
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yale University
Senior High Cost Users (HCU)
Characterizing the Senior High Cost User (HCU) in Ontario
High cost users (HCUs) are a small group of patients who use a disproportionate amount of health care resources. This study is a retrospective population-based matched cohort analysis of newly incident senior High Cost Users…
- Trial name
- NCT02815930
- Testing
- HCU Status
- Volunteers
- 700,000 people
- Sponsor
- McMaster University
Opioid Overdose
Opioid Rapid Response System: Naloxone Training in Communities
The pervasive impact of the opioid epidemic has touched all layers of society for the past two decades, resulting in over 115 deaths daily and imposing annual costs of $78.5 billion.
- Trial name
- NCT06238128
- Testing
- Opioid Rapid Resonse System (ORRS) training, Non-active opioid overdose response training
- Where
- United States
- Volunteers
- 773 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Behavior
Evaluating New Mexico's Recidivism Reduction Program
A a multi-site trial to measure the efficacy of the Recidivism Reduction Program, a prison based, twenty-one module reentry program operated by the New Mexico Department of Corrections.
- Trial name
- RRP (NCT01357291)
- Testing
- Recidivism Reduction Program, Business-as-usual
- Where
- 4 sites in United States
- Volunteers
- 159 people
- Sponsor
- Pepperdine University
HIV
Computer-Assisted HIV Prevention for Young Drug Users
In this study, the investigators are developing and evaluating an interactive, computer-assisted HIV, STD and disease prevention program for young substance abusers that incorporates effective components of both prevention…
- Trial name
- NCT00182585
- Testing
- computer-based HIV, STD & Hepatitis Education, educator-delivered HIV, STD and Hepatitis education
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Development and Research Institutes, Inc.
Bronchopulmonary Dysplasia, Vitamin D Overdose
25OH Vitamin D Overdoses and Risk of Bronchopulmonary Dysplasia or Death
Several studies have demonstrated that vitamin D deficiency at birth is a risk factor of bronchopulmonary dysplasia. However, in an animal model of bronchopulmonary dysplasia vitamin D overdose has also been associated with an…
- Trial name
- 25OHVDORBPDD (NCT05944055)
- Testing
- Is 25 OH vitamin D overdose a risk factor of bronchopulmonary dysplasia or death ?
- Where
- France
- Volunteers
- 173 people
- Sponsor
- Hospices Civils de Lyon
HIV
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
PRO 140 2102 is a phase 2b, national, multicenter, randomized, double-blind, placebo-controlled study in order to evaluate the safety and efficacy of PRO 140 (anti-CCR5 monoclonal antibody) administered subcutaneously as an…
- Trial name
- NCT01272258
- Testing
- PRO 140
- Where
- United States
- Sponsor
- CytoDyn, Inc.